Quarterly Activities Report

For the period ending 31 December 2021

- **ResAppDx now live on Alodokter and Doctors on Demand's telehealth platforms**
- **Janssen Pharmaceutica NV to use ResAppDx technology in a respiratory syncytial virus (RSV) clinical trial**
- **Emerging markets distribution agreement signed with Sanrai International**
- **Partnership with Carepath Technologies GmbH for remote monitoring and management of COPD patients**
- **Completed recruitment in clinical studies in India and the United States to develop an instant smartphone-based COVID-19 screening test**
- **Customer receipts for the quarter increased to $124,000 (Q1: $7,000)**

Brisbane, Australia, 28 January 2022 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to provide an activities update for the three month period ended 31 December 2021 ("Q2 FY2022").

OPERATIONAL HIGHLIGHTS

ACUTE RESPIRATORY DIAGNOSIS

ResAppDx now live on telehealth platforms in Europe, Australia and Indonesia

During the quarter, ResApp worked closely with the teams at Alodokter and Doctors on Demand to complete the integration of ResAppDx into their telehealth platforms. Alodokter is Indonesia's largest telehealth provider, connecting more than 50,000 doctors and 1,500 clinics with millions of Indonesian patients. Doctors on Demand offers both direct-to-consumer and business-to-business offerings for virtual primary care in Australia with leading Australian corporates as its customers.

In January, these integrations were completed and ResAppDx is now live on major telehealth platforms in Switzerland (Medgate), Australia (Coviu, Phenix and Doctors on Demand) and Indonesia (Alodokter). ResApp is also in advanced discussions with a number of other telehealth providers in Europe, Asia and Australia.

Janssen Pharmaceutica NV to use ResAppDx in RSV clinical trial

In November, ResApp signed a three-year, non-exclusive licensing agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the use of its ResAppDx technology in a respiratory syncytial virus (RSV) clinical trial. ResAppDx will be used in a clinical trial conducted by Janssen to assess the respiratory

symptoms of a cohort of patients with a range of respiratory diseases, including RSV. The trial will be conducted in the United States, Europe, South America and Asia-Pacific.

Emerging markets distribution agreement signed with Sanrai International
In December, ResApp entered into a three-year distribution agreement with Sanrai International to distribute ResAppDx in emerging markets. Sanrai is headquartered in New York and has a network of regional offices and partners in Latin America, Africa, the Middle East and South Asia.

This month, Sanrai exhibited ResAppDx at Arab Health at The Dubai World Trade Centre. Arab Health is the largest healthcare event in the Middle East and North Africa, bringing together over 56,000 healthcare professionals. ResApp supported Sanrai with attendance on their stand.

Continued engagement with emerging telehealth players
In January, ResApp signed a binding letter of intent (LOI) with Homify, a Philippines-based telehealth startup. Homify will integrate ResAppDx into their telehealth services which they plan to launch mid 2022. ResApp also continues to work with Workplace Medicine Australia (WMA) on their planned launch of their holistic workplace health and wellbeing management platform, Medetective. In February 2021, WMA decided to broaden its proposed business plan to create an expanded offering for patients, clinicians and corporate partners. WMA's telehealth platform is still under development by WMA, with a launch date not currently set.

Pre-submission meeting with the US FDA
In February 2021, ResApp submitted a pre-submission meeting request with the United States (US) Food and Drug Administration (FDA) to progress the potential clearance of a prescription-only software as a medical device application to detect lower respiratory tract illness in children and adults. The pre-submission meeting was held in January. During the meeting ResApp received feedback from the FDA on potential approval pathways for the application and other requirements. ResApp expects to continue to engage with the FDA to progress clearance.

CHRONIC RESPIRATORY DISEASE MONITORING AND MANAGEMENT

Partnership with Carepath Technologies GmbH for COPD monitoring
In November, ResApp signed a joint development and pilot agreement with Berlin-based company Carepath Technologies GmbH. Under the agreement, Carepath will integrate ResApp's smartphone-based respiratory diagnostic test ResAppDx in their NELA platform and perform a pilot in Germany on the remote monitoring and management of chronic obstructive pulmonary disease (COPD) patients.

In addition to using ResAppDx to monitor patients, the pilot will collect longitudinal COPD data from patients which will potentially allow ResApp to incorporate additional functionality into ResAppDx tailored to the monitoring and management of these COPD patients.

COVID-19 INSTANT SCREENING TEST

Completion of recruitment in COVID-19 studies in India and the United States

During the quarter, ResApp continued recruitment in its COVID-19 studies in India and the United States. These studies aim to collect cough sounds and polymerase chain reaction (PCR) COVID-19 test results to train an algorithm to instantly identify COVID-19 using only a smartphone.

In November, ResApp completed recruitment of 337 patients (including over 200 COVID-19 positive) cases in the study in India. In January, ResApp completed recruitment of 261 (including 112 COVID-19 positive) cases in the US study.

ResApp is now using this data, as well as datasets collected pre-COVID-19, to build, train and validate algorithms for the detection and monitoring of COVID-19. Importantly, ResApp is using existing pre-COVID-19 datasets which contain patients with other lower respiratory tract infections to test and validate algorithms to ensure that its COVID-19 algorithms are specific to COVID-19 infection.

Establishment of a COVID-19 Scientific Advisory Board

In December, ResApp announced the establishment of a COVID-19 Scientific Advisory Board (SAB). The COVID-19 SAB includes leading clinicians from Australia, Europe and the United States who will provide scientific and clinical advice to ResApp on its COVID-19 programs.

SLEEP APNOEA SCREENING

Update on SleepCheckRx US FDA 510(k) premarket notification submission

In October 2021, ResApp submitted a 510(k) premarket notification submission to the US FDA for SleepCheckRx, a prescription-only, software-as-a-medical device (SaMD) smartphone application for at-home sleep apnoea screening. In December, ResApp received a request for additional information from the FDA and ResApp held a meeting with the FDA to clarify this request in January. ResApp was pleased with the outcome of the meeting and will submit a response to the request this quarter. Based on FDA timelines, ResApp expects a decision from the FDA shortly thereafter.

COMPANY

$818,826 R&D tax incentive refund received

During the quarter, ResApp received $818,826 from its research and development (R&D) tax incentive claim for the financial year ending 30 June 2021.

SECOND QUARTER FINANCIAL RESULTS

Receipts from customers for the quarter totalled $124,000 (Q1: $7,000), which comprised of payments from customers for SleepCheck downloads and ResAppDx use, and an advanced payment from Janssen.

Overall cash decrease was $1,062,000 (Q1: $2,151,000), with net cash used in operating activities totalling $969,000 (Q1: $2,104,000). Research and development payments increased to $697,000 (Q1: $558,000). Advertising and marketing costs decreased to $36,000 (Q1: $53,000). Staff costs increased to $1,068,000 (Q1: $982,000). The company made payments of $163,000 to directors during the period ($50,000 for non-executive director fees and $113,000 for executive director fees).

ResApp retained a cash balance of $3.4m at the end of the quarter.

MANAGEMENT COMMENTARY

CEO and Managing Director Dr Tony Keating said: *"In this quarter we finalised the integration of ResAppDx into two additional telehealth platforms – Alodokter in Indonesia and Doctors on Demand in Australia. We were excited to see these two integrations launch in January. We now have ResAppDx being used by a growing number of patients and doctors in Europe, Australia and Asia. It's through this use that we will grow trust and confidence in our technology which will drive further adoption. This trust is also reflected in our deal with Janssen which will see leading clinical researchers in the US, Europe, South America and Asia-Pacific use ResAppDx in an RSV clinical trial. With almost 160,000 people dying each year as a consequence of RSV, we are proud to be supporting Janssen in further understanding the impact of RSV on patients.*

"With the continued impact that COVID-19 is having on the global healthcare system, our research and development efforts for the quarter have been focused on our COVID-19 program. We are very pleased with quality of the cough recordings and clinical data obtained from our clinical studies in India and the US. We believe that the combination of this data with our pre-COVID-19 Australian data gives us a unique advantage in developing the only truly COVID-19 specific cough sound-based algorithm for use on a smartphone. We are excited about the progress we've made in algorithm development and are looking forward to sharing our results in the near future."

CONFERENCE CALL DETAILS

Shareholders are invited to join a conference call hosted by Managing Director and CEO, Dr Tony Keating at 11:00am Australian Eastern Daylight Time (AEDT) today. Shareholders can pre-register for the call by following the link below. Registered participants will receive a calendar notification with dial-in details and a PIN to access the call.

https://s1.c-conf.com/diamondpass/10019084-djsm213.html

###

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and

SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
ResApp Health Limited	
ABN	**Quarter ended ("current quarter")**
51 094 468 318	**31 December 2021**

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (6 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	124	131
1.2	Payments for		
	(a) research and development	(697)	(1,255)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	(36)	(89)
	(d) leased assets	-	-
	(e) staff costs	(1,068)	(2,050)
	(f) administration and corporate costs	(111)	(633)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	4
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	819	819
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(969)**	**(3,073)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(13)	(22)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	(41)	(41)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(54)**	**(63)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Payment of lease liability	(39)	(77)
3.10	**Net cash from / (used in) financing activities**	**(39)**	**(77)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	4,436	6,587
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(969)	(3,073)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(54)	(63)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(39)	(77)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**3,374**	**3,374**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	3,374	4,436
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**3,374**	**4,436**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(163)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 above includes Directors fees and salaries (including superannuation) for Managing Director and Executive Director, Corporate Affairs.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(969)
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,374
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	3,374
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**3**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

28 January 2022

Date: .....

Tony Keating

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.